Its inhaled insulin will succeed wher...

Its inhaled insulin will succeed where Big Pharma failed, MannKind says

There are 1 comment on the The Indianapolis Star story from Jun 1, 2009, titled Its inhaled insulin will succeed where Big Pharma failed, MannKind says. In it, The Indianapolis Star reports that:

Will a small California biotech get the last laugh on Eli Lilly and Co., Pfizer, Novo Nordisk and the rest of Big Pharma? Or will it just be the latest to learn a tough lesson: that new diabetes drugs that seem like breakthroughs on paper often face a bumpy road with patients, doctors and health insurers? For more than a decade, MannKind Corp.

Join the discussion below, or Read more at The Indianapolis Star.

Jolly Rancher

San Jose, CA

#1 Jun 1, 2009
According Al Mann, Chairman and CEO of Mannkind Corp, a billionaire with an incredible track record, Afresa will be a multi-billion dollar revenue drug at a minimum. Increasingly, endocrinologists are understanding that insulin is the ideal treatment of type 2 diabetes, but, unfortunately, present day fast acting insulins aren't fast enough. Afresa is the solution to this problem. Early stage type 2 patients will take inhalable insulin. And Afresa will be covered by healtrh insurance companies because the impliations are improved overall health, thus reduced costs.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

MannKind Discussions

Title Updated Last By Comments
News If Approved -- FDA Drug Labeling Could Decide U... (Feb '10) Feb '10 Reen 1
More from around the web